High eradication rate of H. pylori with moxifloxacin-based treatment: A randomized controlled trial

Wiener Klinische Wochenschrift

Volumn 119, Issue 11-12, 2007, Pages 372-378

  Bago, Petra ^a   Vcev, Aleksandar ^b   Tomic, Monika ^c   Rožankovic, Marjan ^a   Marušić, Marinko ^a   Bago, Josip ^a  

^a Croatian Academy of Medical Sciences   (Croatia)

^b University Hospital   (Croatia)

^c UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

Author keywords

Helicobacter pylori eradication; Moxifloxacin; Primary antibiotic resistance; Proton pump inhibitors

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; MOXIFLOXACIN;

ABDOMINAL PAIN; ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SENSITIVITY; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PREVALENCE; PRURITUS; RANDOMIZED CONTROLLED TRIAL; STOMACH BIOPSY; VOMITING;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; QUINOLINES; TREATMENT OUTCOME;

EID: 34447622804     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00508-007-0807-2     Document Type: Article

References (32)

1. Axon AT, O'Morain CA, Bardhan KD, Crowe JP, Beattie AD, Thompson RP, et al (1997) Randomized controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ 314: 565-568
2. Van der Hulst RW, Rauws EA, Koycu B, Keller JJ, Bruno MJ, Tijssen JG, et al (1997) Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow up study. Gastroenterology 113: 1082-1086
3. Malfertheiner P, Megraud F, O'Morain C, et al (2002) Current concepts in the management of Helicobacter pylori infection - The Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 16: 167-180
4. Graham DY (1998) Therapy of Helicobacter pylori: current status and issues. Gastroenterology 118 [Suppl 1]: S2-S8
5. Graham DY (1998) Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 115: 1272-1277
6. Megraud F, Doermann HP (1998) Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut 43 [Suppl 1]: S61-S65
7. Ducons JA, Santolaria S, Guirao R, Ferrero M, Montoro M, Gomollon F (1999) Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of one week lansoprazole, amoxicillin and clarithromycin in active peptic ulcer. Aliment pharmacol Ther 13: 775-780
8. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ, Saeed ZA, et al (1992) Factors influencing the eradication of H. pylori with triple therapy. Gastroenterology 102: 493-496
9. Cammarota G, Cianci R, Cannizzaro O, et al (2000) Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicopacter pylori infection. Aliment Pharmacol Ther 14: 1339-1343
10. Di Caro S, Zocco AM, Cremonini F, et al (2002) Levofloxacin based regimens for eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 14: 1309-1312
11. Di Caro S, Ojjeti V, Zocco MA, et al (2002) Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 16: 527-532
12. Nista EC, Candelli M, Zocco MA, Cazzato IA, Cremonini F, et al (2005) Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 21: 1241-1247
13. Ball P (2000) Moxifloxacin: an 8-methoxyquinolone antibacterial with enhanced potency. Int J Clin Pract 54: 329-332
14. Edlum C, Beyer G, Hiemer-Bau M, et al (2000) Comparative effects of moxifloxacin and clarithromycin on the normal intestinal microflora. Scand J Infect Dis 32: 81-85
15. Moore RA, Beckthold B, Wong S, et al (1995) Nucleotide sequence of the gyrA gene and characterization of ciprofloxacin-resistant mutants of Helicobacter pylori. Antimicrob Agents Chemother 39: 107-111
16. Kusters JG, Kuipers EJ (2001) Antibiotic resistance of Helicobacter pylori. J Appl Microbiol 90: 134S
17. Debets-Ossenkopp YJ, Herscheid A, Pot RGJ, et al (1999) Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline and trovafloxacin in The Netherlands. J Antimicrob Chemother 43: 511-560
18. Teare L, Peters T, Saverymuttu S, et al (1999) Antibiotic resistance in Helicobacter pylori. Lancet 353: 242
19. Pilloto A, Rassu M, Leandro G, et al (2000) Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU: Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 32: 763-768
20. Cabrita J, Oleastro M, Matos R, et al (2000) Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999). J Antimicrob Chemother 46: 1029-1031
21. Bago J, Halle ZB, Strinic D, et al (2002) The impact of primary resistance on the efficacy of ranitidine bismuth citrate vs. omeprazole-based 1-week triple therapies in H. pylori eradication-a randomized controlled trial. Wien Klin Wochenschr 114: 448-453
22. Bago J, Galovic A, Halle ZB, et al (2004) Comparison of the efficacy of 250 mg and 500 mg clarithromycin used with lansoprasole and amoxicillin in eradication regimens for Helicobacter pylori infection. Wien Klin Wochenschr 116: 495-499
23. Megraud F (2003) Surveillance de la resistance de Helicobacter pylori aux antibiotiques. Surveillance nationale des maladies infectieuses 1998-2000. Institute de Veille Sanitaire, St. Maurice, France, pp 327-329
24. Gupta VK, Dhar A, Srinivasan S, Rattan A, Sharma MP (1997) Eradication of H. pylori in a developing country: comparison of lansoprazole versus omeprazole with nor-floxacin, in a dual therapy study. Am J Gastroenterol 92: 1140-1142
25. Ahuja V, Dhar A, Bal C, Sharma MP (1998) Lanzoprazole and secnidazole with clarithromycin, amoxicillin or pefloxacin in the eradication of Helicobacter pylori in a developing country. Aliment Pharmacol Ther 12: 551-555
26. Cheon JH, Kim N, Lee DH, Kim JM, et al (2006) Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection. Helicobacter 11: 46-51
27. Von Keutz E, Schluter G (1999) Preclinical evaluation of moxifloxacin, a novel fluoroquinolone. J Antimicrob Chemother 43 [Suppl B]: 91-100
28. Nightingale CH (2000) Moxifloxacin, a new antibiotic designed to treat community-acquired respiratory tract infections: a review of microbiologic and pharmacokinetic-pharmacodynamic characteristics. Pharmacotherapy 20: 245-256
29. Blondeau JM, Laskowiski R, Bjarnason J, et al (2000) Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4151 Gram-negative and Gram-positive organisms. Int J Antibicrob Agents 14: 45-50
30. Tankovic J, Lascols C, Sculo Q, et al (2003) Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori. Antibicrob Agents Chemother 47: 3942-3944
31. Boyanova L, Mentis A, Gubina M, et al (2002) The status of antimicrobial resistance of Helicobacter pylori in Eastern Europe. Clin Microbiol Infect 8: 388-396
32. Cellini L, Grande R, Di Campli E, et al (2006) Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy. Scand J Gastroenterol 41: 280-287